Auction Technology Group suitor FitzWalter Capital walks away
proactiveinvestors.co.uk
Want to monitor TGTX?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor TGTXtg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes.